LCAR-M61S + LCAR-M61D

**LCAR-M61S + LCAR-M61D** is a combination of two autologous CAR-T (chimeric antigen receptor T cell) therapies being developed for the treatment of relapsed or refractory multiple myeloma. Both components are cell therapies designed to recognize and eliminate malignant plasma cells. This investigational combination targets both CD19 and GPRC5D, offering a dual-targeting approach in multiple myeloma, potentially addressing tumor heterogeneity and resistance. The therapy is currently under study in a Phase 1 open-label clinical trial to assess safety, tolerability, pharmacokinetics, and antitumor efficacy. The originator and active developer is Legend Biotech (Nanjing Legend Biotech), with clinical studies sponsored by Chinese academic centers such as Jiangsu Provincial People's Hospital[1][2][3][4][7][10].